Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 19;13(11):e073969.
doi: 10.1136/bmjopen-2023-073969.

Does Chinese herbal medicine (CHM) reduce colorectal adenoma (CRA) recurrence: protocol of a registry-based, cohort study and a qualitative interview

Yi Cheng  1   2 , Yuan Ming Di  1 , Anthony Lin Zhang  1 , Peixin Hu  2 , Jiahao Mo  3 , Haiyan Zhang  2   4 , Charlie Changli Xue  5   2 , Beiping Zhang  6   4
Affiliations

Does Chinese herbal medicine (CHM) reduce colorectal adenoma (CRA) recurrence: protocol of a registry-based, cohort study and a qualitative interview

Yi Cheng et al. BMJ Open. .

Abstract

Introduction: Colorectal adenoma (CRA) is a precancerous lesion for colorectal cancer. Endoscopic resection is the first-line treatment for CRA. However, CRA recurrence rate is high. This proposed study aims to determine if Chinese herbal medicine (CHM) reduces CRA recurrence.

Methods and analysis: This project encompasses an observational, registry-based, cohort study and a nested qualitative study. The cohort study aims to include 364 postpolypectomy CRA participants at Guangdong Provincial Hospital of Chinese Medicine (GPHCM), China, with a follow-up phase of up to 1 year. In addition to routine care, these participants will receive a CHM treatment prescribed by experienced Chinese medicine (CM) clinicians. The CHM treatment encompasses CHM products and CHM formulae according to CM syndromes. The primary outcome is CRA recurrence rate at 1 year after enrolment. Secondary outcomes include characteristics of recurrent CRA, incidence of colorectal polyp (except for CRA), incidence of advanced CRA, incidence of colorectal cancer, improvement of gastrointestinal symptoms commonly seen in CRA patients, faecal occult blood test result, lipid level, fasting plasma glucose level, uric acid level, carcinoembryonic antigen, carbohydrate antigen 19-9, quality of life and safety evaluations. Logistic regression analysis will be used to explore the correlation between exposure and outcome. Qualitative interviews will be conducted among approximate 30 CRA patients from the cohort study and 10 CM practitioners in Department of Gastroenterology at GPHCM. Thematic analysis will be used to analyse qualitative data.

Ethics and dissemination: Ethical approval has been obtained from the Human Research Ethics Committee (HREC) of GPHCM (YF2022-320-02) and registered at Royal Melbourne Institute of Technology (RMIT) HREC. The results will be disseminated in peer-reviewed journals and international academic conferences.

Trial registration number: ChiCTR2200065713.

Keywords: COMPLEMENTARY MEDICINE; Gastroenterology; Gastrointestinal tumours; Protocols & guidelines.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow chart. CHM, Chinese herbal medicine. CM, Chinese medicine. CRA, colorectal adenoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Tanaka S, Saitoh Y, Matsuda T, et al. . Evidence-based clinical practice guidelines for management of colorectal polyps. J Gastroenterol 2021;56:323–35. 10.1007/s00535-021-01776-1 - DOI - PMC - PubMed
    1. Dekker E, Tanis PJ, Vleugels JLA, et al. . Colorectal cancer. The Lancet 2019;394:1467–80. 10.1016/S0140-6736(19)32319-0 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Jasperson KW, Tuohy TM, Neklason DW, et al. . Hereditary and familial colon cancer. Gastroenterology 2010;138:2044–58. 10.1053/j.gastro.2010.01.054 - DOI - PMC - PubMed
    1. Graff RE, Möller S, Passarelli MN, et al. . Familial risk and heritability of colorectal cancer in the nordic twin study of cancer. Clin Gastroenterol Hepatol 2017;15:1256–64. 10.1016/j.cgh.2016.12.041 - DOI - PMC - PubMed

Publication types

Substances